Literature DB >> 20386557

Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO.

Shabari Tipnis1, Chandra Viswanathan, Anish S Majumdar.   

Abstract

Umbilical cord is a rich source of mesenchymal stromal or stem cells (MSCs) that can be used for developing allogeneic cell therapy to treat intractable diseases. In this report, we present evidence that umbilical cord-derived MSCs (UCMSCs) possess important immunomodulatory properties that may enable them to survive in an allogeneic environment. UCMSCs do not express human leukocyte antigen (HLA)-DR and co-stimulatory molecules CD80 and CD86 that are required for T-cell activation. More importantly, UCMSCs constitutively express a negative regulator of T-cell activation, B7-H1, and its expression is increased after interferon-γ (IFN-γ) treatment. In addition, IFN-γ treatment induced indoleamine 2,3-dioxygenase (IDO) and HLA-DR expression in UCMSCs. Neither control nor IFN-γ-treated UCMSCs stimulated allogeneic T-cell proliferation, and both cell populations inhibited third-party dendritic cell (DC)-mediated allostimulatory activity. Addition of a B7-H1-specific blocking antibody or an IDO inhibitor, 1 methyl tryptophan (1-MT) abrogated the T-cell immunosuppressive activity of these cells. Furthermore, UCMSCs prevented the differentiation and maturation of peripheral blood monocyte-derived DCs, and augmented the generation of regulatory T cells (Tregs) in culture. The immunosuppressive effects of UCMSCs are largely mediated by cell-to-cell contact, although some inhibitory activity was observed with cell-free supernatant. Our study suggests that these immunomodulatory properties of UCMSCs could potentially improve the outcome of allogeneic stem cell therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20386557     DOI: 10.1038/icb.2010.47

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  74 in total

1.  Differentiation of umbilical cord mesenchymal stem cells into steroidogenic cells in comparison to bone marrow mesenchymal stem cells.

Authors:  X Wei; G Peng; S Zheng; X Wu
Journal:  Cell Prolif       Date:  2012-02-13       Impact factor: 6.831

2.  Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells.

Authors:  Reine El Omar; Yu Xiong; Gabriel Dostert; Huguette Louis; Monique Gentils; Patrick Menu; Jean-François Stoltz; Émilie Velot; Véronique Decot
Journal:  Immunol Cell Biol       Date:  2015-10-29       Impact factor: 5.126

Review 3.  Stem cells for brain repair in neonatal hypoxia-ischemia.

Authors:  L Chicha; T Smith; R Guzman
Journal:  Childs Nerv Syst       Date:  2013-11-01       Impact factor: 1.475

Review 4.  Biological functions of mesenchymal stem cells and clinical implications.

Authors:  Abderrahim Naji; Masamitsu Eitoku; Benoit Favier; Frédéric Deschaseaux; Nathalie Rouas-Freiss; Narufumi Suganuma
Journal:  Cell Mol Life Sci       Date:  2019-05-04       Impact factor: 9.261

Review 5.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

Review 6.  The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord.

Authors:  Ariff Bongso; Chui-Yee Fong
Journal:  Stem Cell Rev Rep       Date:  2013-04       Impact factor: 5.739

7.  Umbilical cord matrix derived mesenchymal stem cells can change the cord blood transplant scenario.

Authors:  Shabari Tipnis; Chandra Viswanathan
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

8.  Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders.

Authors:  Milad Riazifar; M Rezaa Mohammadi; Egest J Pone; Ashish Yeri; Cecilia Lässer; Aude I Segaliny; Laura L McIntyre; Ganesh Vilas Shelke; Elizabeth Hutchins; Ashley Hamamoto; Erika N Calle; Rossella Crescitelli; Wenbin Liao; Victor Pham; Yanan Yin; Jayapriya Jayaraman; Jonathan R T Lakey; Craig M Walsh; Kendall Van Keuren-Jensen; Jan Lotvall; Weian Zhao
Journal:  ACS Nano       Date:  2019-05-29       Impact factor: 15.881

9.  Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium.

Authors:  Daniel Hao Lin; Arijit Biswas; Mahesh Choolani; Chui-Yee Fong; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2017-12       Impact factor: 5.739

Review 10.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.